ADHD is a life-long disorder that presents in early childhood. One in twenty children have ADHD, but even in well-resourced countries only 25% of children with ADHD will receive a diagnosis and access to treatment. Non-treatment has significant lifetime adverse impacts.

Current practice in diagnosing and treating childhood ADHD is problematic. Clinical decisions are based on subjective reporting from parents and teachers, placing young children at high risk for both under and over treatment. First-line treatment is primarily medication. These treatments are effective but carry risk. Safe and effective monitoring of treatment response and adverse effects in children is nearly impossible within the constraints of current resources, especially using current paper-based reporting regimes. PACE (Paediatic Actigraphy for Clinical Evaluation), is a unique, unobtrusive wearable-digital platform which will revolutionise diagnosis and monitoring of ADHD.